Browse the evidence

Semaglutide demonstrates superior efficacy compared to Liraglutide in reducing hemoglobin A1c (HbA1c) levels, though it shows no significant difference in weight loss or fasting blood sugar (FBS) reduction compared to Liraglutide.

If you are managing Type 2 Diabetes without metformin, switching from Liraglutide to Semaglutide is likely to improve your blood sugar control (HbA1c) more effectively. However, do not expect significantly more weight loss from this switch alone, as both drugs appear to offer similar weight reduction benefits.

Semaglutide demonstrates superior efficacy compared to Dulaglutide in reducing both HbA1c and Fasting Blood Sugar (FBS), but shows no significant difference in weight loss or BMI reduction.

If you are using Dulaglutide and your blood sugar (HbA1c and FBS) is not well-controlled, switching to Semaglutide may offer better glycemic results. However, if your primary goal is weight loss, switching is unlikely to yield additional weight reduction compared to staying on Dulaglutide.

Higher BMI and central obesity are strongly associated with poor glycemic control (HbA1c ≥ 7%) in Japanese adults with Type 2 Diabetes, with over 50% of obese patients failing to meet glycemic targets.

If you have Type 2 Diabetes and are in an obesity class (BMI ≥ 25 kg/m² in Japan), your risk of having high blood sugar (HbA1c ≥ 7%) is over 50%. Managing your body weight is a critical step to improving your glycemic control, especially if you are under 45 years old.

Younger adults (18-44 years) with Type 2 Diabetes and obesity exhibit significantly higher rates of poor glycemic control compared to older adults, despite having higher mean BMI and waist circumference.

If you are under 45 and have Type 2 Diabetes, your blood sugar control is likely worse than older patients with the disease, especially if you carry extra weight around your waist. You need to prioritize weight management and dietary habits more aggressively than older patients to achieve similar glycemic targets.

Liraglutide 3.0 mg administered subcutaneously once daily produces significant but numerically lower weight loss compared to semaglutide and is less cost-effective, though it remains a safe and efficacious option for obesity management.

Liraglutide 3.0mg once daily is an effective treatment for obesity, producing an average 5.6kg weight loss. It is less effective than semaglutide and tirzepatide. It remains a safe option, particularly for those who may not respond as well to other agents or have specific contraindications.

Dietary protein quality is determined by essential amino acid content and digestibility (DIAAS), with plant proteins generally having lower bioavailability than animal proteins due to antinutrients.

Understand that plant proteins are generally less bioavailable than animal proteins due to antinutrients. To maximize benefit, eat a variety of plant proteins (legumes, grains, nuts) and consider processing methods (heating, fermentation) that improve digestibility. This is especially important for older adults.

Higher estimated glucose disposal rate (eGDR), indicating lower insulin resistance, is independently associated with a reduced risk of incident cardiovascular disease in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.

For individuals with metabolic risk factors (obesity, high blood pressure, or pre-diabetes), improving insulin sensitivity is a primary strategy for preventing heart disease. While eGDR is a clinical metric, the underlying principle is that reducing insulin resistance—through weight management, physical activity, and dietary quality—lowers cardiovascular risk. This benefit is most pronounced in early stages of metabolic dysfunction (CKM 0-1).

In individuals with Type 2 Diabetes, the 'obesity paradox' exists where the lowest mortality risk is observed in the BMI range of 25–35 kg/m2, but this is largely explained by higher cardiorespiratory fitness (CRF) rather than body weight itself.

Do not fear being overweight if you are fit. In Type 2 Diabetes, the lowest mortality risk is found in those with a BMI of 25-35, but this is because they tend to be more fit. Focus on building fitness. An obese person with high fitness has lower mortality risk than a normal-weight person with low fitness.

Tirzepatide treatment significantly reduces the prevalence of metabolic syndrome in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

If you have type 2 diabetes, tirzepatide (a once-weekly injection) is highly effective at reducing the cluster of risk factors that make up metabolic syndrome (like high blood sugar, high blood pressure, and high triglycerides). It works better than standard insulin or other common diabetes medications in clinical trials. While lifestyle changes are important, they are often not enough on their own to resolve metabolic syndrome, making this medication a powerful tool for improving your cardiovascular risk profile.

Inter-set rest intervals greater than 60 seconds provide a small but detectable hypertrophic benefit for upper and lower limb muscles compared to shorter rest intervals, primarily by preserving volume load.

If your goal is maximum muscle growth, rest 2-3 minutes between sets. While resting less than 60 seconds still works, resting longer allows you to maintain more weight and reps (volume load), leading to slightly better growth, especially in arms and legs. There is no extra benefit to resting longer than 90 seconds.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) significantly reduce hepatic fat content and resolve NASH in patients with NAFLD, primarily through delayed gastric emptying and direct metabolic effects on the liver.

If you have NAFLD or NASH, especially if you are overweight or have type 2 diabetes, GLP-1 receptor agonists like semaglutide (once weekly) and liraglutide are currently the most promising pharmacological treatments for resolving liver fat and NASH. While they can cause temporary gastrointestinal issues like nausea, clinical trials show they significantly improve liver outcomes compared to placebo. Discuss these options with your doctor, as they may offer resolution of steatosis and metabolic improvement.

Incretin receptor agonists (IRAs), including GLP-1RAs and dual GIP/GLP-1RAs, reduce the risk of major adverse cardiovascular events (MACE) and improve lipid profiles and blood pressure in patients with type 2 diabetes.

If you have Type 2 Diabetes and are at risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide, semaglutide, or dulaglutide). These medications not only help control blood sugar but have been proven in large studies to significantly reduce the risk of heart attacks, strokes, and cardiovascular death. They also help lower blood pressure and improve cholesterol levels. While they are often injectable (with some oral options available), the cardiovascular protection they offer is a major benefit for patients with existing heart conditions.

Statin therapy is safe and effective for cardiovascular risk reduction in patients with MASLD and MASH, and elevated transaminases should not prevent prescription.

If you have fatty liver disease (MASLD/MASH), do not avoid statins due to fear of liver damage. Statins are safe, effective for heart health, and may even improve liver markers. Consult your doctor for appropriate intensity based on your overall cardiovascular risk.

Once-weekly semaglutide (2.4 mg) significantly improves health-related quality of life and reduces body weight in obese patients with HFpEF.

If you are obese and have HFpEF, ask your doctor about semaglutide (Ozempic/Wegovy). The STEP-HFpEF trial showed that taking 2.4 mg once weekly significantly improved quality of life and reduced body weight by over 13% compared to placebo.

Dual or triple agonists targeting GLP-1, GIP, and/or Glucagon receptors (GCGR) produce superior weight loss compared to selective GLP-1 receptor agonists alone.

Newer obesity medications that target multiple receptors (like GLP-1, GIP, and Glucagon) are more effective for weight loss than older single-target drugs. These include Tirzepatide and Retatrutide, which are approved or in advanced trials for obesity and diabetes.

Rapid weight loss from GLP-1 and dual/triple agonists can lead to significant loss of lean muscle mass, necessitating strategies to preserve muscle.

While GLP-1 and dual/triple agonists are effective for fat loss, they can also cause significant muscle loss. Patients should consider resistance training and discuss muscle-preserving strategies with their healthcare provider.

Lower intertemporal discount rates (higher patience) are associated with the selection of foods with higher nutritional quality, independent of active health consideration.

People who are naturally more patient (low discounters) tend to choose healthier foods. This trait is stable but can be influenced by interventions like episodic future thinking, which asks individuals to imagine detailed future experiences, thereby reducing impulsive choices and promoting healthier diets.

Actively considering health outcomes during food choice leads to longer decision times, increased use of nutrition information, and consideration of healthier product sets, distinguishing it from habitual decision-making.

Healthy choices often require more time and effort than habitual ones. If you find yourself spending more time looking at labels and considering health impacts, this is a sign of active, model-based decision-making that leads to better outcomes. You can facilitate this by using simple visual cues that make health information easy to process, reducing the cognitive load.

Intermittent diet breaks may reduce psychological disinhibition (loss of control over eating) compared to continuous energy restriction, although this comes at the cost of a longer total intervention duration.

If you struggle with losing control over your eating (disinhibition) while dieting, scheduled diet breaks might help you stay more in control psychologically than continuous dieting. However, this strategy requires 8 weeks to achieve what continuous dieting does in 6 weeks, so you must be willing to extend your total dieting time.

Set-volume equated hip thrust and back squat training produce similar gluteus maximus hypertrophy, despite hip thrusts eliciting greater acute muscle activation (sEMG).

If your goal is glute growth, you don't need to choose between squats and hip thrusts based on 'activation.' Both exercises produce similar glute growth when you perform the same number of sets and reps to failure. Squats may be better for overall leg development (quads/adductors), while hip thrusts might be preferred for those with back pain or specific mobility issues. Focus on progressive overload and volume equivalence rather than chasing 'burn' or activation feelings.

The Edmonton Obesity Staging System (EOSS) provides a more comprehensive clinical management framework than BMI alone by categorizing obesity based on health complications.

Ask your doctor to use the Edmonton Obesity Staging System (EOSS) to evaluate your health. This focuses on your specific complications rather than just your weight.

Next-generation incretin-based therapies (GLP-1 RAs like semaglutide and dual GLP-1/GIP agonists like tirzepatide) significantly reduce blood pressure and improve cardiovascular outcomes in patients with hypertension, obesity, or type 2 diabetes, acting through both weight loss and direct tissue effects on the cardiovascular system.

If you have high blood pressure, obesity, or type 2 diabetes, ask your doctor about GLP-1 or GLP-1/GIP medications like semaglutide or tirzepatide. These weekly injections not only help with weight loss but also directly lower blood pressure and protect your heart, often allowing you to reduce or stop other blood pressure medications. The benefits extend beyond weight loss through direct effects on your blood vessels and nervous system.

Testosterone therapy preserves lean mass and reduces fat mass when used as an adjunct to incretin-based weight loss medications, potentially counteracting sarcopenia.

Current evidence does not yet support using testosterone to offset muscle loss from GLP-1 weight loss drugs. Resistance exercise and adequate protein intake are the recommended strategies to preserve muscle mass during weight loss.

Individuals with muscle-specific insulin resistance (Impaired Glucose Tolerance, IGT) achieve greater metabolic improvements on a low-fat, high-fiber diet, whereas those with liver-specific insulin resistance (Impaired Fasting Glucose, IFG) respond better to a monounsaturated fat-enriched diet.

If you have insulin resistance, your specific metabolic defect determines which diet works best. If your blood sugar spikes after meals (Impaired Glucose Tolerance, often linked to muscle insulin resistance), a low-fat, high-fiber diet is likely superior. If your fasting blood sugar is high (Impaired Fasting Glucose, linked to liver insulin resistance), a diet emphasizing monounsaturated fats may be more effective. Standard generic diets often fail because they ignore this distinction.